Avillion LLP
http://avillionllp.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Avillion LLP
Bigger Money: Private Equity Grabs European VC
Deals show large investors’ appetite for early-stage biotech, but can VC and PE rub along?
Carlyle Bets Big On Late-Stage Biotech With Abingworth Buy
Tapping into Abingworth’s pioneering clinical co-development model, the private equity behemoth is using that experience to form Launch Therapeutics which will seek to partner with biotech and biopharma on "best‐in‐class, late‐stage clinical assets [and] bring life‐saving therapies to market better, faster and cheaper."
Hengrui Takes Focused Approach Amid China Inc's Global Drive
China’s largest innovative domestic drug maker will only take global those products that play into its strengths, chairman Piaoyang Sun declares.
AstraZeneca Rejigs Respiratory Franchise With Fresh Covis Deal
Having got hold of two COPD drugs from Spain's Almirall in 2014, AstraZeneca has passed Eklira and Duaklir onto old partner Covis Pharma as it focuses on more targeted respiratory therapies.
Company Information
- Other Names / Subsidiaries
-
- Avillion Group
- Bond Avillion 2 Development LP